Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bilibili Inc (BILI) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance

Bilibili IncTrade
Charles River Laboratories Intl. IncTrade

Price performance (Past 24H)

Key statistics

Bilibili Inc vs Charles River Laboratories Intl. Inc — how do they compare? Bilibili Inc trades at $17.6 (market cap $7.65B), while Charles River Laboratories Intl. Inc trades at $288.87 (market cap $13.46B). The key difference: Charles River Laboratories Intl. Inc is the larger of the two by market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Bilibili Inc nearer its low. Which is the better fit depends on your goals.

BILICRL
Market Cap
$7.65B$13.46B
Sector
MediaHealth
52-Week High
$35.92$282.00
52-Week Low
$15.96$145.57
Enterprise Value
$5.49B$16.30B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bilibili Inc

Bilibili (BILI) trades at $17.61, down 7.27% over 24 hours, reflecting bearish technical signals despite strong analyst support. The company reported Q1 2026 EPS of $0.19, beating expectations, with revenue growth projected to $30.8B in 2026. Profit margins improved to 4.58%, though valuation ratios like P/E of 36.24 remain elevated. Recent news highlights a $300 million share repurchase program and upcoming Q2 earnings on August 27, 2026.

The outlook is mixed: bullish fundamentals from earnings beats and buy-side consensus contrast with near-term technical weakness. Key opportunities include user monetization and AI integration, while risks involve competitive pressure and reliance on Chinese market dynamics. The stock's trajectory hinges on Q2 results delivering sustained margin expansion.

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.

The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.

Returns comparison

Trailing returns across standard periods

About Bilibili Inc

Bilibili is a leading video sharing and online entertainment platform for Gen Z in China. It offers a diverse range of content, including anime, games, and live broadcasting, fueled by a highly engaged community.

Read more on BILI

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL